Please login to the form below

Not currently logged in
Email:
Password:

Mavenclad

This page shows the latest Mavenclad news and features for those working in and with pharma, biotech and healthcare.

Sanofi licences Principia MS drug in $805m deal

Sanofi licences Principia MS drug in $805m deal

The three established players in the oral MS therapy category are also about to see additional competition from new entrant Merck KGaA, which bagged EU approval for Mavenclad (cladribine) in August.

Latest news

  • Merck mulls sale of consumer health division Merck mulls sale of consumer health division

    The news comes a few days after Merck picked up an important new approval for its pharma division in Europe, with the EMA clearing Mavenclad (cladribine) for the treatment of ... It has been suggested that hiving off consumer health would help management

  • Merck gets CHMP backing for long-delayed oral MS drug Merck gets CHMP backing for long-delayed oral MS drug

    Merck gets CHMP backing for long-delayed oral MS drug. Cladribine, which will be branded as Mavenclad, was originally rejected by the committee in 2010. ... The CHMP's recommendation will be referred to the EMA, which is expected to make a final decision

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics